Nexgen Formulations
FDA 503B outsourcing facility
Folcroft, Pennsylvania
Key Takeaways
- FDA-registered 503B outsourcing facility since 2026
- Sterile compounding from bulk substances: Yes
- Not yet inspected by the FDA
About this facility
A 503B outsourcing facility is registered with the FDA under the Drug Quality and Security Act and may compound sterile medications in bulk without patient-specific prescriptions, under cGMP manufacturing standards. How federal compounding status works.
FDA registration and inspection record
- First registered with FDA
- January 15, 2026
- Most recent registration
- January 15, 2026
- Compounds sterile drugs from bulk substances
- Yes
- Last FDA inspection
- Not yet inspected
Nexgen Formulations has registered with the FDA as a 503B outsourcing facility but has not yet been inspected. The FDA inspects registered facilities on a risk-based schedule once drug production and distribution are confirmed.
Compounded peptides and GLP-1s
Nexgen Formulations has not assigned NDCs or filed product reports in the most recent FDA reporting periods. 503B outsourcing facilities are a primary supply route for compounded peptides and GLP-1s during FDA-listed shortages; PeptideGrids grades the evidence for each, including Semaglutide, Tirzepatide, BPC-157, Retatrutide. Browse the GLP-1 and therapeutic peptide databases.
Contact
FDA-registered contact: Salman Patha, 1-610-455-5125. Source: the facility's FDA outsourcing registration.
License verification
503B outsourcing facilities are also licensed by the state board of pharmacy. Verify the current license status of Nexgen Formulations with the Pennsylvania State Board of Pharmacy.
503B facilities in Pennsylvania
Pennsylvania has 5 FDA-registered 503B outsourcing facilities in the PeptideGrids directory. See all 503B facilities in Pennsylvania.
Frequently asked questions
Is Nexgen Formulations registered with the FDA?
Yes. Nexgen Formulations is a registered 503B outsourcing facility, first registered with the FDA on January 15, 2026 and most recently registered on January 15, 2026.
Has Nexgen Formulations been inspected by the FDA?
Nexgen Formulations has registered with the FDA but has not yet been inspected as a 503B outsourcing facility.
Has Nexgen Formulations had any FDA drug recalls?
No FDA drug recalls are matched to Nexgen Formulations in the openFDA enforcement database.
What does Nexgen Formulations compound?
Nexgen Formulations has not filed product reports with NDC-assigned drugs in the most recent FDA reporting periods.
Where is Nexgen Formulations located?
Nexgen Formulations is located in Folcroft, Pennsylvania.
Registration and inspection data verified against the FDA list of registered outsourcing facilities on June 6, 2026.
PeptideGrids is independent and not affiliated with, endorsed by, or sponsored by Nexgen Formulations. Listings, registration, inspection, and recall data are reported from public FDA records for informational purposes only. A recall or inspection finding is not an accusation of current wrongdoing. This is not medical or legal advice. To request a correction, see our corrections policy.